The pharmaceutical manufacturer Eli Lilly announced on Wednesday that its obesity drug tirzepatide, or Zepbound, provided considerable relief to overweight or obese people who had obstructive sleep apnea, or episodes of stopped breathing during sleep. The results, from a pair of yearlong clinical trials, could offer a new treatment option for some 20 million Americans […]
Read More